» Articles » PMID: 24369532

Chromogenic in Situ Hybridization and P16/Ki67 Dual Staining on Formalin-fixed Paraffin-embedded Cervical Specimens: Correlation with HPV-DNA Test, E6/E7 MRNA Test, and Potential Clinical Applications

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2013 Dec 27
PMID 24369532
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Although HPV-DNA test and E6/E7 mRNA analyses remain the current standard for the confirmation of human papillomavirus (HPV) infections in cytological specimens, no universally adopted techniques exist for the detection of HPV in formalin-fixed paraffin-embedded samples. Particularly, in routine laboratories, molecular assays are still time-consuming and would require a high level of expertise. In this study, we investigated the possible use of a novel HPV tyramide-based chromogenic in situ hybridization (CISH) technology to locate HPV on tissue specimens. Then, we evaluate the potential usefulness of p16(INK4a)/Ki-67 double stain on histological samples, to identify cervical cells expressing HPV E6/E7 oncogenes. In our series, CISH showed a clear signal in 95.2% of the specimens and reached a sensitivity of 86.5%. CISH positivity always matched with HPV-DNA positivity, while 100% of cases with punctated signal joined with cervical intraepithelial neoplasia grade 2 or worse (CIN2+). p16/Ki67 immunohistochemistry gave an interpretable result in 100% of the cases. The use of dual stain significantly increased the agreement between pathologists, which reached 100%. Concordance between dual stain and E6/E7 mRNA test was 89%. In our series, both CISH and p16(INK4a)/Ki67 dual stain demonstrated high grade of performances. In particular, CISH would help to distinguish episomal from integrated HPV, in order to allow conclusions regarding the prognosis of the lesion, while p16(INK4a)/Ki67 dual stain approach would confer a high level of standardization to the diagnostic procedure.

Citing Articles

Evaluation of Automatic Signal Detection of In Situ Hybridization for Detecting HPV DNA in Cervical Tissue Derived from Patients with Cervical Intraepithelial Neoplasia.

Przybylski M, Millert-Kalinska S, de Mezer M, Krzyzaniak M, Kurzawa P, Zurawski J Cancers (Basel). 2024; 16(20).

PMID: 39456579 PMC: 11506503. DOI: 10.3390/cancers16203485.


High-Risk HPV CISH Detection in Cervical Biopsies with Weak and/or Focal p16 Immunohistochemical Positivity.

Cabibi D, Giannone A, Quattrocchi A, Lo Coco R, Formisano E, Porcasi R Int J Mol Sci. 2024; 25(10).

PMID: 38791395 PMC: 11121605. DOI: 10.3390/ijms25105354.


Mathematical Modelling of Cervical Precancerous Lesion Grade Risk Scores: Linear Regression Analysis of Cellular Protein Biomarkers and Human Papillomavirus / RNA Staining Patterns.

Bumrungthai S, Ekalaksananan T, Kleebkaow P, Pongsawatkul K, Phatnithikul P, Jaikan J Diagnostics (Basel). 2023; 13(6).

PMID: 36980391 PMC: 10047622. DOI: 10.3390/diagnostics13061084.


Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization.

Ren H, Pors J, Chow C, Ta M, Stolnicu S, Soslow R J Pathol Transl Med. 2020; 54(6):480-488.

PMID: 32854489 PMC: 7674758. DOI: 10.4132/jptm.2020.07.18.


Putative Role of Circulating Human Papillomavirus DNA in the Development of Primary Squamous Cell Carcinoma of the Middle Rectum: A Case Report.

Ambrosio M, Vernillo R, De Carolis S, Carducci A, Mundo L, Ginori A Front Oncol. 2019; 9:93.

PMID: 30847303 PMC: 6394246. DOI: 10.3389/fonc.2019.00093.


References
1.
Kuo K, Hsiao C, Lin C, Kuo L, Huang S, Lin M . The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome. Mod Pathol. 2008; 21(4):376-86. DOI: 10.1038/modpathol.3800979. View

2.
de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N . Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7):453-9. DOI: 10.1016/S1473-3099(07)70158-5. View

3.
Arbyn M, Sasieni P, Meijer C, Clavel C, Koliopoulos G, Dillner J . Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006; 24 Suppl 3:S3/78-89. DOI: 10.1016/j.vaccine.2006.05.117. View

4.
Qu W, Jiang G, Cruz Y, Chang C, Ho G, Klein R . PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997; 35(6):1304-10. PMC: 229739. DOI: 10.1128/jcm.35.6.1304-1310.1997. View

5.
Zappacosta R, Caraceni D, Ciccocioppo L, Ottaviantonio M, Conti F, Andreozzi S . Is HPV-DNA testing a useful tool in predicting low-grade squamous intraepithelial lesion outcome? A retrospective longitudinal study. Int J Immunopathol Pharmacol. 2010; 23(1):317-26. DOI: 10.1177/039463201002300130. View